#CD20
LightNews LightNews
davidmogeladze.bsky.social
bioengineer.org/ensitrelvir-...
Ensitrelvir Rescued Three Lymphoma Patients With Remdesivir-Refractory
A Japanese case series reports that three men with follicular lymphoma treated with anti-CD20 antibodies improved after ensitrelvir when remdesivir failed to control their persistent COVID-19.
bioengineer.org
November 6, 2026 at 10:53 PM
rhea-mare.bsky.social
私は貸したものことごとく返ってこないから中々人には貸さなくなったけど、そう言うのがあるから借りたものは速やかに返却します

しかしほんとに帰ってこない
CD20枚くらいかえってきてないし、ゲームも10本くらい帰ってこないままね

私の覚醒とifはどこ旅してるんだろう
November 6, 2026 at 10:32 PM
rheumcat.bsky.social
⭐ SLE - Obinutuzumab - Furie NEJM

Approved for LN

Deep B cell depletion really works

#ACR26
Obinutuzumab trial summary: Type II anti‑CD20 monoclonal antibody approved for lupus nephritis with more profound B‑cell depletion than rituximab; phase 3 double‑blind RCT across 14 countries (N=303) in active SLE (excluding proliferative/membranous LN); primary outcome SRI‑4 at week 52. Comparison of SRI‑4 response and glucocorticoid sparing at week 52 showing higher rates with obinutuzumab: SRI‑4 77% vs placebo 53%, and GC ≤7.5 mg from weeks 40–52 80% vs 54%; placebo orange, obinutuzumab blue. Obinutuzumab produced higher rates at week 52: remission (DORIS) 34% vs placebo 14%, and lupus low disease activity state 58% vs placebo 25%.
November 8, 2026 at 1:00 PM
rcatanho.bsky.social
Rituximab se asocia con un riesgo elevado de enfermedad intestinal inflamatoria comparado con otras terapias modernas para la esclerosis múltiple, por lo que se deben vigilar los síntomas GI durante la terapia anti-CD20 #antiCD20 #IBD #MS jamanetwork.com/journals/jam...
Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in MS
This cohort study investigates if anti-CD20 treatment is associated with an increase in the risk of inflammatory bowel disease in individuals with multiple sclerosis (MS).
jamanetwork.com
November 5, 2026 at 3:12 PM
moltherapy.bsky.social
Are entirely virus-free CAR T cells as good as lentiviral transduced universal cells?
Qasim and colleagues compared anti-CD20 41BB-CD3ζ-CAR T cells inserted at TRAC- or CD3ζ- by targeted CRISPR insertion against existing lentiviral benchmarks. Non-viral manufacturing resulted in products with comparable in vitro function but leukaemia clearance was generally less robust in vivo. The findings highlight the promise of non-viral approaches but suggest further refinements and careful benchmarking against lentiviral approaches will be essential for human comparisons.
dlvr.it
November 6, 2026 at 1:08 PM
brandon-beaber.bsky.social
Kesimpta vs. ocrevus in multiple sclerosis. This observational study from the Danish MS registry found they were about equally effective. Ocrevus was associated with marginally fewer relapses but similar rates of progression and MRI activity. www.neurology.org/doi/10.1212/...
Ofatumumab vs Ocrelizumab in Relapsing-Remitting Multiple Sclerosis | Neurology
Background and ObjectivesB-cell–depleting therapy with anti-CD20 monoclonal antibodies is a highly effective and increasingly used treatment strategy for multiple sclerosis (MS); however, comparative ...
www.neurology.org
November 6, 2026 at 11:57 PM
meducationai.bsky.social
Lovely thread from @scienceyael.bsky.social on why CD19 CAR T may reset autoimmunity where rituximab doesn't. A related pearl for heme fellows: CD19 stays on plasmablasts after CD20 is lost, so CD19 targeting reaches deeper into the B lineage.
November 4, 2026 at 6:26 PM
scienceyael.bsky.social
12/ A possible reason antibodies fail: Latency III drives NF-κB survival signaling, and EBV+ cells upregulated CD55, tied to rituximab resistance in B cell cancers.

Four anti-CD20/CD19 antibodies killed EBV+ targets poorly in vitro. CAR T cells and blinatumomab did fine.
November 2, 2026 at 9:33 PM
karencheng.bsky.social
📢 SUMMIT trial recruiting in the US!

Ublituximab, an engineered anti-CD20 antibody designed for enhanced B-cell depletion, is being studied in anti-SRP+ and anti-HMGCR+ IMNM.

Interested? Discuss benefits and risks with your doctor!

#IMNM #Myositis
November 3, 2026 at 9:35 PM
gavingiovannoni.bsky.social
#MS_Selfie Q&A 196 - fenebrutinib and smouldering MS

Would you switch from an anti-CD20 to fenebrutinib based on these data? gavingiovannoni.substack.com/p/q-and-a-19...
Q&A 196 - fenebrutinib and smouldering MS
Would you switch from an anti-CD20 to fenebrutinib based on these data?
gavingiovannoni.substack.com
November 2, 2026 at 3:17 PM
reason3.bsky.social
連番合わせてCD20、円盤6でいぐ！！これで落ちたらオッドナンバー跡地に骨埋めてください
October 31, 2026 at 1:27 PM
jdevos.bsky.social
🚨 Gilead/Kite has announced a partial clinical hold on the Ph2 PALISADES-1 and Ph3 PALISADES-2 trials of KITE-753 in rDLBCL following grade 3–4 ICANS. KITE-753 is a next-generation, dual targeting (CD19 and CD20) and dual costimulation (CD28 41BB).

buff.ly/kbIHF4W
Gilead reveals partial clinical hold on 2 CAR-T cell therapy trials
Gilead Sciences announced on its third-quarter earnings call Oct. | Gilead Sciences announced on its third-quarter earnings call Oct. 29 that the company has placed a partial clinical hold on two…
buff.ly
November 2, 2026 at 1:00 PM
palamedesreport.org
Antiviral and inflammatory immune signatures in anti-CD20-treated multiple sclerosis: a cross-sectional study.
J Neurol

This week in Multiple Sclerosis and Neuroimmunology: palamedesreport.org/this-week/multiple-sclerosis
pubmed.ncbi.nlm.nih.gov/42881295

#MedSky #neurology #multiplesclerosis
This week in Multiple Sclerosis and Neuroimmunology: Antiviral and inflammatory immune signatures in anti-CD20-treated multiple sclerosis: a cross-sectional study. J Neurol. AI-generated. Verify against the paper. In relapsing MS, ocrelizumab was associated with selectively lower EBV-specific CD4+ T-cell counts and stimulation index while CMV- and SARS-CoV-2-specific responses were comparable across groups; no effect sizes were reported. Design: Cross-sectional study at two neurological centers in Rome, with an immunophenotyping cohort (45 untreated, 25 anti-CD20-treated) and a separate antiviral cohort (24 untreated, 13 treated, 19 healthy donors); no follow-up (cross-sectional). Comparisons by Kruskal-Wallis with Dunn's correction; Spearman correlations. Population: Adults with relapsing multiple sclerosis, untreated or treated with anti-CD20 therapy (all ocrelizumab), plus healthy donors in the antiviral cohort. Age and sex distribution not reported in the abstract; no dementia population studied. Ranked by PubMed attention — the views of everyone using PubMed — not by quality, importance or correctness.
October 29, 2026 at 1:00 PM
bibliotecahuvh.bsky.social
Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, www.sciencedirect.com/science/arti... #hvhebron #hemat [Text complet]
www.sciencedirect.com
October 29, 2026 at 12:15 PM
midgardfinance.com
🧬 #biotech #pharma

🇺🇸 #$BIIB Biogen: Q3 revenue +11% to $2,804m. #Syfovre and #Empaveli, bought with Apellis in May, added $243m of the $269m. #Spinraza and #Skyclarys nearly offset the fall in multiple sclerosis. Low end of 2026 EPS guidance raised to $12.20.

midgardfinance.com/companies/BIIB/
Horizontal bar chart titled "Biogen: change in Q3 revenue by line", ranked, with "Total revenue" first in grey at +$269m (+10.6%): Syfovre, Empaveli (bought) +$243m, Rare disease +$143m (+26.8%), Zurzuvae +$29m (+52.6%), Leqembi share +$26m (+60.2%), Anti-CD20 programmes +$3m (+0.7%), Manufacturing, other −$2m (−1.0%), Biosimilars −$31m (−15.7%), Multiple sclerosis −$142m (−13.4%). Blue bars are increases and purple bars decreases; every bar is labelled with its value.
October 28, 2026 at 3:30 PM
gavingiovannoni.bsky.social
#MS_Selfie Q&A 195: Anti-CD20-induced colitis and hypogammaglobulinaemia

Immune-mediated colitis is now a recognised side effect of ocrelizumab and other anti-CD20 therapies and is listed in ocrelizumab’s US label. => gavingiovannoni.substack.com/p/q-and-a-19...
Q&A 195: Anti-CD20-induced colitis and hypogammaglobulinaemia
Immune-mediated colitis is now a recognised side effect of ocrelizumab and the other anti-CD20 therapies and is listed in ocrelizumab’s US label.
gavingiovannoni.substack.com
October 26, 2026 at 4:59 AM
nplusodin.bsky.social
При терапии рассеянного склероза препаратом моноклональных антител к В-клеточному антигену CD20 ритуксимабом повышен риск воспалительных заболеваний кишечника, особенно болезни Крона

https://nplus1.ru/news/2026/10/26/rituximab-rrms-and-ibd
template_text_news
October 26, 2026 at 8:50 AM
aacrjournals.bsky.social
This is a commentary to: Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22

➡️Read it here: buff.ly/6m6NUBy
Safety and Clinical Outcomes of a First-in-Human Trial of Point-of-Care Manufactured Trispecific CAR T Cells Targeting CD19, CD20, and CD22
First-in-human trial of a trispecific CAR T-cell therapy demonstrates feasibility of rapid point-of-care manufacturing, safety, and preliminary efficacy of CD19/20/22 CAR T-cell therapy of B-cell…
buff.ly
October 27, 2026 at 12:01 AM
moltherapy.bsky.social
NIS reporter gene PET imaging reveals expansion kinetics and localization of anti-CD20 CAR-T in mice and nonhuman primates
Duncan and colleagues use longitudinal PET/CT imaging of Rhesus macaques to track autologous T cells co-expressing a CAR construct and the sodium-iodine symporter (NIS) that allows in vivo radioactive labeling. This first-in-large-animal study found different localization patterns based upon the costimulatory domain contained within the CAR construct
dlvr.it
October 26, 2026 at 1:06 PM
sburtey.bsky.social
Très intéressant papier pour les prescripteurs de rituximab en chronique que nous pouvons être, augmentation des MICI dans la SEP traitée par rituximab. jamanetwork.com/journals/jam...
Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in MS
This cohort study investigates if anti-CD20 treatment is associated with an increase in the risk of inflammatory bowel disease in individuals with multiple sclerosis (MS).
jamanetwork.com
October 24, 2026 at 5:50 AM
schwierig.bsky.social
Familienangehörige und enge Kontaktpersonen ab dem Alter von 6 Monaten, bei denen nach einer Covid-19-Impfung keine schützende Immunantwort zu erwarten ist.

Rituximab = CD20-Antikörper -> vollständige B-Zelldepletion = keinerlei Bildung neutralisierender Antikörper, damit keine Impfantwort
October 23, 2026 at 2:32 PM
gavingiovannoni.bsky.social
#MS_SELFIE_RESEARCH - MSToronto26: Remibrutinib news

ARR about 47% higher on remibrutinib (RR 1.47, 1.09–1.98 vs pooled anti-CD20). New/enlarging T2 lesions 2–4× higher. CDP similar => gavingiovannoni.substack.com/p/mstoronto2...
MSToronto26: Remibrutinib
ARR about 47% higher on remibrutinib (RR 1.47, 1.09–1.98 vs pooled anti-CD20). New/enlarging T2 lesions 2–4× higher. CDP similar.
gavingiovannoni.substack.com
October 23, 2026 at 5:12 PM
carpenter22.bsky.social
Multiple Sclerosis Anti-CD20 Drug Linked to Bowel Disease Risk www.medpagetoday.com/meetingcover...
Multiple Sclerosis Anti-CD20 Drug Linked to Bowel Disease Risk
IBD risk was higher with rituximab versus other MS drugs, but cumulative incidence was low
www.medpagetoday.com
October 23, 2026 at 11:18 PM
medpagetoday.com
The anti-CD20 agent rituximab was associated with a higher risk of IBD in people with relapsing-remitting MS compared with other disease-modifying treatments, a population-based cohort study in Sweden showed. #MSToronto2026
https://www.medpagetoday.com/meetingcoverage/ectrims/123547
Multiple Sclerosis Anti-CD20 Drug Linked to Bowel Disease Risk
IBD risk was higher with rituximab versus other MS drugs, but cumulative incidence was low
www.medpagetoday.com
October 23, 2026 at 9:31 PM
ki.se
Link to publication ⬇️
jamanetwork.com/journals/jam...
Risk of Inflammatory Bowel Disease After Anti-CD20 Treatment in MS
This cohort study investigates if anti-CD20 treatment is associated with an increase in the risk of inflammatory bowel disease in individuals with multiple sclerosis (MS).
jamanetwork.com
October 23, 2026 at 9:23 AM